Hepatitis B and C Diagnostics Industry – Treatment Analysis,Research,Review to 2023

WiseGuyReports.Com Publish a New Market Research Report On –“ Hepatitis B and C Diagnostics Industry – Treatment Analysis,Research,Review to 2023”.

Description:-

Hepatitis B diagnostic tests include HBV serologic tests, molecular deoxyribonucleic acid (DNA) tests, histology tests, and laboratory tests. HBV serologic tests involve the measurement of antigens and antibodies. Hepatitis C diagnostic tests include anti-HCV serologic test, HCV recombinant immunoblot assay (RIBA) antibody test, and HCV molecular ribonucleic acid (RNA) testing. Anti-HCV is the serologic test used for screening.

Scope of the Report:
This report studies the Hepatitis B and C Diagnostics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Hepatitis B and C Diagnostics market by product type and applications/end industries.

Get a Sample Report @ https://www.wiseguyreports.com/sample-request/3443190-global-hepatitis-b-and-c-diagnostics-market-2018

For more information or any query mail at sales@wiseguyreports.com

The increasing demand for molecular diagnostic of HBV (hepatitis B virus) and HCV (hepatitis C virus) infections is one of the primary drivers for the growth of this market. Molecular diagnosis simplifies sample preparation for high-volume testing and includes identification and profiling of causative agents of infection and the quantification of pathogens to monitor durability of therapy; thus, resulting in sales of around 60% of the overall molecular diagnosis market. Additionally, new companies are also focusing on the development of new products, which, in turn, is expected to change market dynamics for the diagnosis of HBV and HCV infections. For instance, Cepheid recently announced a quantitative test that offers on-demand molecular testing for confirmation of infection and monitoring of HCV and has obtained CE-IVD (in vitro diagnostics) status under the European Directive on in-vitro diagnostic medical devices, making it one of the leading platforms for molecular diagnosis.

Increasing incidence of HBV and HCV infections in the Americas will contribute to the growth of the diagnostic market. The Americas will dominate the market, accounting for half of the total market share by 2023. The recent increase in blood transfusion will result in the adoption of third-generation hepatitis C diagnostic tests like HCV enzyme immunoassay that contribute to the growth of the market in this region. Also, the implementation of biomarker-based POC (point-of-care) tests initiated by the government and non-profit organizations, is also expected to drive the market growth as the products are highly accessible and easy to use.
The global Hepatitis B and C Diagnostics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Hepatitis B and C Diagnostics.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Roche Diagnostics
Abbott
Siemens
Qiagen
Alere
bioMérieux
Cepheid
Chembio Diagnostics
DiaSorin
Enzo Life Sciences
Hologic
MedMira
OraSure Technologies
Quest Diagnostics
Quidel Corp
Randox Laboratories

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Hepatitis B
Hepatitis C

Market Segment by Applications, can be divided into
Immunodiagnostics
Nucleic Acid Test (NAT)

Enquiry About Report @ https://www.wiseguyreports.com/enquiry/3443190-global-hepatitis-b-and-c-diagnostics-market-2018

Table Of Contents – Major Key Points

1 Hepatitis B and C Diagnostics Market Overview
1.1 Product Overview and Scope of Hepatitis B and C Diagnostics
1.2 Classification of Hepatitis B and C Diagnostics by Types
1.2.1 Global Hepatitis B and C Diagnostics Revenue Comparison by Types (2017-2023)
1.2.2 Global Hepatitis B and C Diagnostics Revenue Market Share by Types in 2017
1.2.3 Hepatitis B
1.2.4 Hepatitis C
1.3 Global Hepatitis B and C Diagnostics Market by Application
1.3.1 Global Hepatitis B and C Diagnostics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Immunodiagnostics
1.3.3 Nucleic Acid Test (NAT)
1.4 Global Hepatitis B and C Diagnostics Market by Regions
1.4.1 Global Hepatitis B and C Diagnostics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Hepatitis B and C Diagnostics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Hepatitis B and C Diagnostics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Hepatitis B and C Diagnostics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Hepatitis B and C Diagnostics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Hepatitis B and C Diagnostics Status and Prospect (2013-2023)
1.5 Global Market Size of Hepatitis B and C Diagnostics (2013-2023)

2 Manufacturers Profiles
2.1 Roche Diagnostics
2.1.1 Business Overview
2.1.2 Hepatitis B and C Diagnostics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Roche Diagnostics Hepatitis B and C Diagnostics Revenue, Gross Margin and Market Share (2016-2017)
2.2 Abbott
2.2.1 Business Overview
2.2.2 Hepatitis B and C Diagnostics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Abbott Hepatitis B and C Diagnostics Revenue, Gross Margin and Market Share (2016-2017)
2.3 Siemens
2.3.1 Business Overview
2.3.2 Hepatitis B and C Diagnostics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Siemens Hepatitis B and C Diagnostics Revenue, Gross Margin and Market Share (2016-2017)
2.4 Qiagen
2.4.1 Business Overview
2.4.2 Hepatitis B and C Diagnostics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Qiagen Hepatitis B and C Diagnostics Revenue, Gross Margin and Market Share (2016-2017)
2.5 Alere
2.5.1 Business Overview
2.5.2 Hepatitis B and C Diagnostics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Alere Hepatitis B and C Diagnostics Revenue, Gross Margin and Market Share (2016-2017)
2.6 bioMérieux
2.6.1 Business Overview
2.6.2 Hepatitis B and C Diagnostics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 bioMérieux Hepatitis B and C Diagnostics Revenue, Gross Margin and Market Share (2016-2017)
2.7 Cepheid
2.7.1 Business Overview
2.7.2 Hepatitis B and C Diagnostics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Cepheid Hepatitis B and C Diagnostics Revenue, Gross Margin and Market Share (2016-2017)

Continued……

Buy 1-user PDF @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=3443190

ABOUT US:
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

Office No.528,Amanora Chambers,Magarpatta Road,Hadapsar,Pune-411028.

This release was published on openPR.